Details for New Drug Application (NDA): 215781
✉ Email this page to a colleague
NDA 215781 describes TROSPIUM CHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Granules, Padagis Us, Upsher Smith Labs, Utopic Pharms, Apotex, Chartwell Rx, Glenmark Pharms Ltd, Heritage Pharms Inc, Invagen Pharms, and Macleods Pharms Ltd, and is included in twelve NDAs. It is available from nineteen suppliers. Additional details are available on the TROSPIUM CHLORIDE profile page.
The generic ingredient in TROSPIUM CHLORIDE is trospium chloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
The generic ingredient in TROSPIUM CHLORIDE is trospium chloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
Summary for 215781
| Tradename: | TROSPIUM CHLORIDE |
| Applicant: | Chartwell Rx |
| Ingredient: | trospium chloride |
| Patents: | 0 |
Pharmacology for NDA: 215781
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Suppliers and Packaging for NDA: 215781
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TROSPIUM CHLORIDE | trospium chloride | TABLET;ORAL | 215781 | ANDA | Zameer Pharmaceuticals LLC | 90096-141 | 90096-141-60 | 60 TABLET, FILM COATED in 1 BOTTLE (90096-141-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Feb 16, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
